Navigation Links
Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings

HASBROUCK HEIGHTS, NJ (June 21, 2007) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that detailed results from the Company’s recently completed studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at a series of upcoming U.S. urology meetings, beginning in September at the South Central American Urological Association Meeting in Colorado Springs. These independent podium presentations will be given by leading clinical research urologist principal investigators from the clinical trials. Further specific details on the upcoming presentations will be announced at a later date.

The Company has completed a series of studies of the safety and efficacy of NX-1207 for BPH, including two Phase 1-2 studies and a Phase 2 study as well as several follow-up studies of patients for up to 3 ½ years after NX-1207 treatment. The Company’s recently completed prospective randomized placebo controlled Phase 2 U.S. study confirmed the positive efficacy and safety results for NX-1207 from earlier studies. After 3 months, patients treated with NX-1207 had a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement was significantly greater than the 3.5 to 5 points typically reported for currently approved drugs for BPH. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. In particular, patients given NX-1207 had no (0%) significant sexual side effects. Follow-up studies have provided data showing that NX-1207 can provide enduring benefits of up to 42 months or more following treatment.

The AUA Symptom Score is a standardized and widely accepted questionnaire used to assess the severity of BPH symptoms and the efficacy of treatments for BPH. The AUA Score consists of seven questions relating to frequency of problems with urination such a
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
2. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
3. Nymox Reports Completion of New 42 Month Follow-up Study of NX-1207 for BPH
4. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nymox Announces Data Presented Upcoming Urology Meetings
(Date:9/17/2014)... , Sept. 17, 2014 Women everywhere ... infections are not only uncomfortable, they,re often also embarrassing ... plans. pH-D Feminine Health Support ( http://ph-defense.com ) is ... It is an all-natural, homeopathic product. ... common symptoms of vaginal infection. In many cases, the ...
(Date:9/17/2014)... LOS ANGELES and LEIPZIG, ... Inc. today announced that it has entered into ... for the development of antibody-based imaging agents to ... "Our collaboration with Novotectid expands ImaginAb,s capability to ... the immune-oncology and autoimmune disease areas. The ability ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... Ind., Oct. 20, 2011 Hill-Rom Holdings, Inc., (NYSE: ... a management presentation at the Credit Suisse,s 2011 Healthcare ... p.m. ET. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at ...
... Oct. 20, 2011 The Academy of Managed ... Conference in Atlanta. The conference, Oct. 19-21, draws ... and features a wide range of programs and ... sessions, student pharmacist programming, networking events and other ...
Cached Medicine Technology:Academy of Managed Care Pharmacy Opens 2011 Educational Conference in Atlanta 2
(Date:9/17/2014)... In its latest blog post, Best Drug Rehabilitation , ... by during a stay in rehab can make a big ... highlighting a member of the therapeutic care team that is ... the country and around the world: dogs. , ... heart rate, and stress levels in recovering addicts,” commented Best ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... Dennis Thompson ... News) -- Exposure in the womb to household chemicals ... of developing asthma, Columbia University researchers reported in a ... increased risk of developing asthma between age 5 and ... high levels of two phthalates (pronounced thal-ates), the researchers ...
(Date:9/17/2014)... 17, 2014Scientists at The Scripps Research Institute (TSRI) ... that is powerfully effective against vancomycin-resistant strains of ... vancomycin analog appears to have not one but ... bacteria probably cannot evolve resistance quickly. , "This ... will still be in clinical use a generation ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... HealthDay Reporter , TUESDAY, Oct. 26 (HealthDay News) ... could be prevented if people followed five simple healthy ... which would improve overall health as well -- include ... maintaining a healthy weight, the researchers say. "Even ...
... respond to hormonal changes and inflammation has been awarded ... five-year study. The research programme at the National ... is led by Professor Julian Davis, a consultant endocrinologist ... of Manchester,s Developmental Biomedicine Research Group. He is ...
... Professor Zhipeng Wu has invented a portable scanner based on radio ... presence of tumours malignant and benign in the breast ... breast cancer detection has been proven by researchers in the US, ... few minutes for an image to be produced, and this had ...
... is not considered effective treatment for KRAS (a gene)-mutated ... colorectal cancer not responding to chemotherapy and a certain ... had longer overall and progression-free survival than patients with ... 27 issue of JAMA . "Recent ...
... TUESDAY, Oct. 26 (HealthDay News) -- Children who survive ... on, a new study suggests. The findings highlight ... among childhood cancer survivors, the researchers said. "Current ... cancer, but we know that many cancer therapies -- ...
... 26 (HealthDay News) -- Primary care doctors earn the ... one reason for U.S. medical students, declining interest in ... at the wages of 6,381 physicians providing patient care ... primary care; surgery; internal medicine and pediatric subspecialties; and ...
Cached Medicine News:Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 3Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Portable breast scanner allows cancer detection in the blink of an eye 2Health News:Colorectal cancer patients with gene mutation show better response to cancer agent 2Health News:Childhood Cancer Survivors Risk Future GI Problems 2Health News:Primary Care MDs at Low End of Pay Scale, Study Finds 2
... androgen secreted into the blood. In males, ... of the testes; in females ca. 50% ... of androstenedione, ca. 25% from the ovary ... The Testosterone ELISA KIT is based on ...
Microalbumin EIA Lipid / Protein Quantification 024-IDC-12...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: